News
Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b trial and potential FDA filing next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback